Host directed therapies: COVID-19 and beyond.

Area of Science:

• Virology and Drug Development
• Infectious Disease Therapeutics
• Molecular Biology

Background:

• The COVID-19 pandemic highlighted the urgent need for effective antiviral therapies.
• Existing antiviral development is lengthy; repurposing drugs and developing broad-spectrum agents are crucial.
• Pathogen-specific antivirals face challenges from drug resistance and limited scope.

Purpose of the Study:

• To review host-directed therapies (HDTs) for viral infections, with a focus on COVID-19.
• To explore strategies for identifying novel host targets for antiviral development.
• To discuss the development of broad-spectrum HDTs for future pandemic preparedness.

Main Methods:

• Literature review of host-directed therapies against viral infections.
• Analysis of viral reliance on host cellular pathways for replication.
• Discussion of target identification and drug development strategies for HDTs.

Main Results:

• Host-directed therapies (HDTs) represent a viable strategy against viral infections by targeting host pathways essential for viral propagation.
• Focusing on host factors offers a path toward developing broad-spectrum antivirals effective against a range of viruses.
• HDTs are particularly relevant for viruses like SARS-CoV-2 that heavily depend on host machinery.

Conclusions:

• Future antiviral drug development should prioritize targeting host pathways to create broad-spectrum, anticipatory therapies.
• HDTs are essential for combating current viral threats like COVID-19 and preparing for future pandemics.
• Identifying and targeting host molecules offers a sustainable approach to antiviral drug discovery.